The Food and Drug Administration visited ART Reproductive Center, LLC in Beverly Hills on April 14 to examine its practices related to human cellular, tissue, and gene therapies, according to data posted on the FDA’s website.
The resulting report found no corrective actions were necessary regarding any of the organization’s management procedures.
The FDA carries out routine inspections of facilities nationwide to verify that workplaces and their products align with laws and regulations aimed at enhancing public health. Outcomes from these inspections are made public.
According to its website, the FDA is a federal agency chiefly tasked with overseeing the safety and quality of human and animal drugs, biological items, medical supplies, and tobacco products.
Information for this article was sourced from the U.S. Food and Drug Administration. The original data can be accessed here.
